These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8224935)

  • 1. Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.
    Steinhorst UH; Hatchell DL; Chen EP; Machemer R
    Graefes Arch Clin Exp Ophthalmol; 1993 Oct; 231(10):591-4. PubMed ID: 8224935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
    Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
    Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit.
    Santana M; Wiedemann P; Kirmani M; Minckler DS; Patterson R; Sorgente N; Ryan SJ
    Graefes Arch Clin Exp Ophthalmol; 1984; 221(5):210-3. PubMed ID: 6489768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naka-Rushton equation parameters in electroretinogram analysis of daunomycin effects on retinal function.
    Gangadhar DV; Wolf BM; Tanenbaum HL
    Doc Ophthalmol; 1989 May; 72(1):61-70. PubMed ID: 2530072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.
    Hui YN; Liang HC; Cai YS; Kirchhof B; Heimann K
    Graefes Arch Clin Exp Ophthalmol; 1993 Feb; 231(2):109-14. PubMed ID: 8444357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina.
    Steinhorst UH; Chen EP; Machemer R; Hatchell DL
    Exp Eye Res; 1993 Apr; 56(4):489-95. PubMed ID: 8500561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.
    Wiedemann P; Sorgente N; Bekhor C; Patterson R; Tran T; Ryan SJ
    Invest Ophthalmol Vis Sci; 1985 May; 26(5):719-25. PubMed ID: 3997421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular toxicity of intravitreal tacrolimus.
    Passos E; Genaidy MM; Peyman GA
    Ophthalmic Surg Lasers; 2002; 33(2):140-4. PubMed ID: 11942546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.
    Khawly JA; Saloupis P; Hatchell DL; Machemer R
    Graefes Arch Clin Exp Ophthalmol; 1991; 229(5):464-7. PubMed ID: 1937080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation.
    Wiedemann P; Kirmani M; Santana M; Sorgente N; Ryan SJ
    Graefes Arch Clin Exp Ophthalmol; 1983; 220(5):233-5. PubMed ID: 6629017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.
    Kirmani M; Santana M; Sorgente N; Wiedemann P; Ryan SJ
    Retina; 1983; 3(4):269-72. PubMed ID: 6201971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermia reduces the occurrence of proliferative vitreoretinopathy in a rabbit model.
    Yoshimura N; Kuriyama S; Ohuchi T; Takemura M; Honda Y; Hiraoka M
    Invest Ophthalmol Vis Sci; 1992 Feb; 33(2):404-9. PubMed ID: 1740372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adriamycin on experimental proliferative vitreoretinopathy in the rabbit.
    Sunalp MA; Wiedemann P; Sorgente N; Ryan SJ
    Exp Eye Res; 1985 Jul; 41(1):105-15. PubMed ID: 4029281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
    Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of vitreolysis and vitreous detachment with hyaluronidase and perfluoropropane gas.
    Kang SW; Hyung SM; Choi MY; Lee J
    Korean J Ophthalmol; 1995 Dec; 9(2):69-78. PubMed ID: 8818320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy.
    Moritera T; Ogura Y; Yoshimura N; Honda Y; Wada R; Hyon SH; Ikada Y
    Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3125-30. PubMed ID: 1399416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease.
    Hui YN; Hu D
    Graefes Arch Clin Exp Ophthalmol; 1999 Jul; 237(7):601-5. PubMed ID: 10424311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye.
    Hida T; Chandler DB; Sheta SM
    Graefes Arch Clin Exp Ophthalmol; 1987; 225(4):303-7. PubMed ID: 3653728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitreoretinal toxicity of basic fibroblast growth factor.
    Borhani H; Peyman GA; Rahimy MH; Beuerman RW
    Int Ophthalmol; 1993 Aug; 17(4):195-9. PubMed ID: 8112966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.